Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant (Q36954706)

17 August 2017

1 reference

title

Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant (English)

1 reference

17 August 2017

0 references

1 reference

Miguel A Rubio

1

1 reference

17 August 2017

Manuel Gargallo

series ordinal

2

1 reference

17 August 2017

Ana Isabel Millán

series ordinal

3

1 reference

17 August 2017

Basilio Moreno

series ordinal

4

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

17 August 2017

Public Health Nutrition

1 reference

17 August 2017

10

1 reference

17 August 2017

10A

1 reference

17 August 2017

1200-1205

1 reference

Orlistat inhibits dietary cholesterol absorption

17 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

Effects of sibutramine treatment in obese adolescents: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Orlistat for obesity: benefits beyond weight loss

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

A systematic review of the clinical effectiveness of orlistat used for the management of obesity.

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies.

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Randomized trial of lifestyle modification and pharmacotherapy for obesity

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

A review of the metabolic effects of sibutramine.

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

QT interval prolongation associated with sibutramine treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Endocannabinoid control of food intake and energy balance

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study

1 reference

https://api.crossref.org/works/10.1017%2FS1368980007000717

7 January 2021

10.1017/S1368980007000717

Identifiers

DOI

1 reference

17 August 2017

1 reference